logo-loader
RNS
viewOncimmune

Oncimmune Hldngs PLC - Featured Presentation at ASCO 2020 Virtual Meeting

RNS Number : 8388M
Oncimmune Holdings PLC
14 May 2020
 

14 May 2020

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

 Featured Presentation at ASCO 2020 Virtual Meeting

 

Oncimmune data shows autoantibodies in patients treated with immune checkpoint inhibitors have utility in predicting treatment response, including immune-related adverse events

 

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces that its data from profiling tumour associated antibodies in melanoma patients receiving immune checkpoint inhibitors has been selected as a featured presentation at the upcoming American Society of Clinical Oncology 2020 ("ASCO") Virtual Scientific Programme, which will take place from May 29 to May 31, 2020.

 

The featured presentation will review data assessing samples from patients receiving either Pembrolizumab, Ipilimumab, Nivolumab monotherapy, or combination therapy of Ipilimumab and Nivolumab, which have been analysed on Oncimmune's proprietary biomarker discovery engine, SeroTag®. The data identified that autoantibodies have a role in predicting clinical outcomes or immune-related adverse events ("irAEs").

 

Prof. Dr. med. Jessica Hassel, Head of Section Dermatology at The National Center for Tumor Diseases (NCT) Heidelberg, Germany will present an abstract (no. 10011) titled: "Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition therapy of metastasized melanoma."

 

This will be the first time that the clinical utility of autoantibodies will have been presented at this prestigious international cancer research conference.

 

Adam M Hill, CEO of Oncimmune said: "This study provides further evidence that autoantibodies play an important role in identifying patients likely to suffer irAEs in response to cancer immunotherapy, this time in patients suffering from melanoma. Importantly, the study also reinforces the evidence base underpinning the utility of tumour related antibodies in predicting clinical responses to commonly used first-line treatment immunotherapies.

 

"Oncimmune is at the forefront in understanding the utility of autoantibodies in a clinical setting. This exciting study demonstrates the strides we have made in unlocking the potential of our autoantibody platform to improve patient outcomes."

 

For further information:

 

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[email protected]

 

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000

 

finnCap (Joint Broker)

Geoff Nash, Matthew Radley, Tim Redfern

+44 (0)20 7220 0500

 

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

+44 (0)20 7332 2500

 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

[email protected]

+44 (0)20 3727 1000

 

 

About Oncimmune

 

Beating cancer, one test at a time

 

The battle against cancer hinges on early detection and then the delivery of effective treatment. Oncimmune is working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease detecting capabilities of the immune system to find cancer in its early stages. Our range of diagnostic tests assist clinicians to identify the presence of cancer four years or more before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.

 

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 158,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled trial for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) ECLS trial of 12,209 high-risk smokers in Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

 

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

 

What is EarlyCDT Lung?

 

A blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.

 

For more information, visit www.oncimmune.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAAJMBTMTMBTJM

Quick facts: Oncimmune

Price: 130.5

Market: AIM
Market Cap: £82.87 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE